维布妥昔单抗联合AVD方案治疗II-IV期HIV相关霍奇金淋巴瘤(AMC 085):开放标签、单臂、多中心1/2期试验的2期结果
这项多中心1/2期研究的2期部分纳入41例未治疗的II-IV期HIV相关经典型霍奇金淋巴瘤患者,接受维布妥昔单抗1.2 mg/kg联合AVD方案治疗6个周期。2年无进展生存率为87%,总生存率为92%,37例完成治疗者均达完全缓解;常见3级及以上不良事件为中性粒细胞减少(44%)、周围感觉神经病变(10%)和发热性中性粒细胞减少(12%),报告1例治疗相关感染死亡。作者认为该方案在HIV-cHL中高度活跃且不良事件可耐受,是重要的治疗选择。
要点
- 维布妥昔单抗-AVD方案在HIV相关经典型霍奇金淋巴瘤中2年无进展生存率87%。
- 37例完成治疗的患者均获得完全缓解,总生存率92%。
- 3级及以上不良事件以中性粒细胞减少(44%)和周围感觉神经病变(10%)为主。
核心结论
- 维布妥昔单抗-AVD方案在HIV相关经典型霍奇金淋巴瘤中高度活跃且不良事件率可耐受,是HIV-cHL患者的重要治疗选择;完全缓解率令人鼓舞,可能与HIV-cHL独特的生物学特征有关;即将获得的5年数据将评估所获结局的可持续性。
研究设计与样本
- 多中心1/2期研究的2期部分,开放标签、单臂设计。
- 纳入18岁及以上、未治疗的II-IV期HIV相关经典型霍奇金淋巴瘤患者,Karnofsky体能状态>30%,CD4+ T细胞计数≥50个/μL,需接受抗逆转录病毒治疗(ART),且未使用强CYP3A4或P-糖蛋白抑制剂。
- 治疗方案为维布妥昔单抗1.2 mg/kg(推荐2期剂量)联合标准剂量AVD,28天为一周期,第1天和第15天给药,共6个周期。
- 2期部分主要终点为2年无进展生存率(PFS),在所有开始治疗的合格参与者中评估;入组已完成;试验注册号NCT01771107。
主要发现
- 2013年3月8日至2019年3月7日,41例患者接受研究治疗,中位随访29个月(IQR 16-38)。
- 34例(83%)为III-IV期,7例(17%)为II期不利型HIV-cHL。
- 37例(90%)完成治疗,完成治疗的37例均获得完全缓解。
- 2年无进展生存率为87%(95% CI 71-94),总生存率为92%(78-97)。
- 最常见的3级或更严重不良事件为周围感觉神经病变(4/41,10%)、中性粒细胞减少(18/41,44%)和发热性中性粒细胞减少(5/41,12%);报告1例治疗相关死亡,原因为感染。
关键数值与推荐
- 维布妥昔单抗推荐2期剂量为1.2 mg/kg,联合标准剂量AVD,28天周期第1天和第15天给药,共6个周期。
- 2期部分主要终点为2年无进展生存率,在所有开始治疗的合格参与者中评估。
- 入组标准包括CD4+ T细胞计数≥50个/μL,需接受ART,且未使用强CYP3A4或P-糖蛋白抑制剂。
临床怎么用
- 作者认为维布妥昔单抗-AVD方案是HIV-cHL患者的重要治疗选择。
- 作者指出完全缓解率令人鼓舞,可能与HIV-cHL独特的生物学特征有关。
- 作者表示即将获得的5年数据将评估所获结局的可持续性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been excluded from these studies. We aimed to understand the activity and safety of brentuximab vedotin-AVD in people living with HIV diagnosed with Hodgkin lymphoma, while focusing on HIV disease parameters and antiretroviral therapy (ART) interactions. METHODS: We present the phase 2 portion of a multicentre phase 1/2 study. Eligible patients were 18 years or older, had untreated stage II-IV HIV-associated cHL (HIV-cHL), a Karnofsky performance status of more than 30%, a CD4+ T-cell count of 50 cells per μL or more, were required to take ART, and were not on strong CYP3A4 or P-glycoprotein inhibitors. Patients were treated intravenously with 1·2 mg/kg of brentuximab vedotin (recommended phase 2 dose) with standard doses of AVD for six cycles on days 1 and 15 of a 28-day cycle. The primary endpoint of the phase 2 portion was 2-year progression-free survival (PFS), assessed in all eligible participants who began treatment. Accrual has been completed. This trial is registered at ClinicalTrials.gov, NCT01771107. FINDINGS: Between March 8, 2013, and March 7, 2019, 41 patients received study therapy with a median follow up of 29 months (IQR 16-38). 34 (83%) of 41 patients presented with stage III-IV and seven (17%) with stage II unfavourable HIV-cHL. 37 (90%) of 41 patients completed therapy, all 37 of whom achieved complete response. The 2-year PFS was 87% (95% CI 71-94) and the overall survival was 92% (78-97). The most common grade 3 or worse adverse events were peripheral sensory neuropathy (four [10%] of 41 patients), neutropenia (18 [44%]), and febrile neutropenia (five [12%]). One treatment-related death was reported, due to infection. INTERPRETATION: Brentuximab vedotin-AVD was highly active and had a tolerable adverse event rate in HIV-cHL and is an important therapeutic option for people with HIV-cHL. The complete reponse rate is encouraging and is possibly related to a unique aspect of HIV-cHL biology. Upcoming 5-year data will evaluate the sustainability of the outcomes obtained. FUNDING: National Institutes of Health and National Cancer Institute.
引用
- Rubinstein PG, Moore PC, Bimali M, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023. PMID: 37532416. doi:10.1016/S2352-3026(23)00157-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。